QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
QQQ   352.01 (+1.16%)
AAPL   180.09 (+1.60%)
MSFT   332.58 (+1.28%)
META   272.61 (+2.98%)
GOOGL   123.72 (+0.69%)
AMZN   122.77 (+1.82%)
TSLA   207.52 (+1.76%)
NVDA   397.70 (+5.12%)
NIO   7.54 (+0.13%)
BABA   82.99 (+4.32%)
AMD   119.47 (+1.07%)
T   15.82 (+0.51%)
F   12.11 (+0.92%)
MU   69.09 (+1.30%)
CGC   0.83 (+0.00%)
GE   104.66 (+3.08%)
DIS   88.59 (+0.72%)
AMC   4.55 (+0.89%)
PFE   38.04 (+0.03%)
PYPL   63.05 (+1.71%)
NFLX   403.13 (+2.00%)
NASDAQ:VECT

VectivBio (VECT) Stock Forecast, Price & News

$16.55
0.00 (0.00%)
(As of 06/1/2023 ET)
Compare
Today's Range
$16.50
$16.80
50-Day Range
$8.25
$16.55
52-Week Range
$4.25
$16.80
Volume
976,363 shs
Average Volume
434,072 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.33

VectivBio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
47.0% Upside
$24.33 Price Target
Short Interest
Healthy
2.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of VectivBio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.80) to ($1.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars


VECT stock logo

About VectivBio (NASDAQ:VECT) Stock

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Receive VECT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VectivBio and its competitors with MarketBeat's FREE daily newsletter.

VECT Stock News Headlines

[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
What 4 Analyst Ratings Have To Say About VectivBio Holding
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
Why Shares of VectivBio Holding Are Up Today
Ironwood Pharma To Acquire VectivBio For $17/Shr In All-cash Deal
VectivBio Holding AG (NASDAQ:VECT) Short Interest Update
Piper Sandler Keeps Their Buy Rating on VectivBio Holding (VECT)
See More Headlines

VECT Price History

VECT Company Calendar

Today
6/01/2023
Next Earnings (Estimated)
7/19/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VECT
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+47.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$27.34 million
Book Value
$6.27 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.10

Key Executives

  • Dr. Luca Santarelli M.D. (Age 53)
    Founder, CEO & Director
  • Ms. Claudia D'Augusta Ph.D. (Age 52)
    Chief Financial Officer
  • Dr. Christian Meyer M.D. (Age 55)
    Ph.D., Chief Operating Officer
  • Dr. Alain Bernard Ph.D. (Age 65)
    Chief Technology Officer
  • Mr. Patrick Malloy
    Sr. VP of Investor Relations & Strategic Communications
  • Mr. Scott Applebaum (Age 55)
    Chief Legal Officer & Corp. Sec.
  • Mr. Michael Steininger
    Sr. VP & Head of HR
  • Mr. Kevin Harris M.B.A. (Age 51)
    Chief Commercial Officer
  • Dr. Sarah Holland Ph.D. (Age 59)
    Chief Bus. Officer
  • Dr. Omar Khwaja M.D. (Age 51)
    Ph.D., Chief Medical Officer













VECT Stock - Frequently Asked Questions

Should I buy or sell VectivBio stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for VectivBio in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VECT shares.
View VECT analyst ratings
or view top-rated stocks.

What is VectivBio's stock price forecast for 2023?

5 equities research analysts have issued 12-month target prices for VectivBio's stock. Their VECT share price forecasts range from $18.00 to $30.00. On average, they expect the company's share price to reach $24.33 in the next year. This suggests a possible upside of 47.0% from the stock's current price.
View analysts price targets for VECT
or view top-rated stocks among Wall Street analysts.

How have VECT shares performed in 2023?

VectivBio's stock was trading at $8.6650 on January 1st, 2023. Since then, VECT stock has increased by 91.0% and is now trading at $16.55.
View the best growth stocks for 2023 here
.

Are investors shorting VectivBio?

VectivBio saw a increase in short interest in May. As of May 15th, there was short interest totaling 580,300 shares, an increase of 123.5% from the April 30th total of 259,700 shares. Based on an average daily trading volume, of 574,800 shares, the short-interest ratio is currently 1.0 days. Approximately 2.1% of the company's stock are sold short.
View VectivBio's Short Interest
.

When is VectivBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023.
View our VECT earnings forecast
.

When did VectivBio IPO?

(VECT) raised $128 million in an initial public offering on Friday, April 9th 2021. The company issued 7,500,000 shares at $16.00-$18.00 per share. BofA Securities, SVB Leerink and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

What is VectivBio's stock symbol?

VectivBio trades on the NASDAQ under the ticker symbol "VECT."

Who are VectivBio's major shareholders?

VectivBio's stock is owned by many different institutional and retail investors. Top institutional investors include CHI Advisors LLC (0.00%), Tekla Capital Management LLC (0.00%), Balyasny Asset Management L.P. (0.95%), Gilder Gagnon Howe & Co. LLC (0.17%), UBS Group AG (0.16%) and Bank of America Corp DE (0.12%).

How do I buy shares of VectivBio?

Shares of VECT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is VectivBio's stock price today?

One share of VECT stock can currently be purchased for approximately $16.55.

How can I contact VectivBio?

The official website for the company is vectivbio.com. The company can be reached via phone at 41-61-551-3030 or via email at ir@vectivbio.com.

This page (NASDAQ:VECT) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -